Hospitals are in desperate search of a drug that can reverse lead poisoning and a sterile fluid required for heart-stopping during bypass surgery. Shortages of certain antibiotics persist following the winter flu season, leaving doctors and patients scrambling for medications to treat ailments like strep throat. Even children’s Tylenol has become increasingly difficult to find.
The United States is facing a significant shortage of numerous medications, with hundreds of drugs appearing on the list. The country’s officials are grappling with a complex and occasionally disrupted supply chain, as well as issues related to quality and finances that result in manufacturing shutdowns.
The seriousness of these shortages has caught the attention of both the White House and Congress. They are investigating the root causes of the struggling generic drug market, which constitutes about 90 per cent of prescriptions in the country. In response, the Biden administration has formed a dedicated team focused on finding long-term solutions to strengthen the pharmaceutical supply chain. This is particularly crucial as the United States heavily relies on medicines and drug ingredients from India and China. Furthermore, over the past few weeks, lawmakers have heard testimonies from experts representing generic drug manufacturers, supply-chain professionals, and patient advocates, all aiming to tackle these concerns.
The scarcity of generic chemotherapy drugs, used for treating bladder, breast, lung, and ovarian cancers, has raised additional concerns. The American Cancer Society has issued a recent warning that these shortages could result in worse outcomes for cancer patients if there are delays in treatment.
According to a recent analysis, the scarcity of certain cancer drugs has become a critical and life-threatening issue for patients nationwide. The American Cancer Society (ACS) and its advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN), have been directly informed by patients and healthcare providers about the impact of these shortages. The drugs in short supply often lack effective alternatives, and delays in treatment could result in worse outcomes, particularly for cancers like triple-negative breast cancer, ovarian cancer, and leukaemia in pediatric patients.
The FDA’s tools to address drug shortages primarily involve collaborating with manufacturers to identify and resolve the causes while urging other manufacturers to increase production. This approach, referred to as “early warning,” constitutes the majority of the FDA’s available strategies.
Both the ACS as well ACS CAN happen to be actively monitoring and engaging in the issue of medical product shortages as part of their mission to improve the lives of individuals with cancer and their families. The ACS is engaging in communication with healthcare systems across the country and directly interacting with patients who reach out to the American Cancer Society National Cancer Information Center (NCIC). At the same time, ACS CAN is actively encouraging Congress to investigate long-term solutions that tackle the root causes of these shortages. In the interim, they encourage collaboration between the industry and healthcare practitioners to identify possible alternatives and prevent delays in cancer patients’ treatments.